CPIX
Cumberland Pharmaceuticals Inc
7.60$
-5.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.3% | -9.1% | +15.9% | -7.7% | +14.9% | +12.2% | -7.5% | -23.5% | +65.0% | -33.2% | -98.2% | – | |
| – | -13.3% | +3.0% | +8.6% | -22.7% | +49.4% | -27.9% | +41.1% | -50.8% | +126.7% | -13.7% | -98.1% | – | |
| – | -6.0% | -11.5% | +17.6% | -4.6% | +9.0% | +21.6% | -14.2% | -17.2% | +56.6% | -37.1% | -98.2% | – | |
| – | -34.3% | -8.4% | -8.6% | +23.3% | -1.0% | +0.2% | +13.4% | -14.6% | +23.6% | -5.9% | -47.1% | – | |
| – | +46.7% | -31.1% | +16.4% | -3.0% | +24.3% | -26.0% | +16.7% | -10.5% | +57.0% | -36.7% | -0.3% | – | |
| – | +37.5% | -37.2% | +4.2% | +3.2% | +8.9% | -12.7% | +6.4% | -3.2% | +38.2% | -19.4% | -68.1% | – | |
| – | – | – | – | – | – | – | -157.9% | – | – | – | – | – | |
| – | +62.4% | -33.7% | +6.6% | +8.7% | +62.5% | -26.6% | -33.1% | +0.1% | +3.0% | -24.0% | -99.2% | – | |
| – | – | – | – | – | – | – | -158.2% | – | – | – | – | – | |
| – | +259.7% | -54.2% | +0.0% | 0.0% | -598.1% | – | +0.0% | 0.0% | +310.0% | -83.3% | 0.0% | – | |
| – | – | – | – | – | – | – | -158.9% | – | – | – | – | – | |
| – | -845.6% | – | – | -97.2% | +253.6% | +5,817.8% | -74.4% | -213.8% | – | -3,809.9% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.